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Abstract
Introduction: Treatment of chronic hepatitis C (CH-C) with
peginterferon α (Peg-IFN) and ribavirin leads to a sustained
virological response (SVR) in 50% of patients and depends on
HCV and host factors. Polymorphism of the IL28B gene is
associated with eradication of HCV and SVR.
Aim: The objective of this study was to examine patients from
the region of southern Poland and determine whether CH-C
therapy depends on the genetic variants of IL28B and
whether this polymorphism may predict SVR.
Material and methods: One hundred forty-two patients
with CH-C and the genotype 1b HCV were treated with Peg-
IFN and ribavirin for 48 weeks. IL28B rs12979860 polymor-
phisms (C/T) were tested by PCR-RFLP. The HCV-RNA and
alanine aminotransferase (ALT) levels were measured
before treatment and after 12, 48 and 72 weeks.
Results: Viral load before and after 12 weeks of therapy was
higher in the genotypes T/C and T/T than in C/C. 71.1% of
patients with the genotype C/C achieved SVR vs. 41.4% with
the genotype T/C and 23.5% with T/T. Patients with the geno-
type C/C responded better to treatment as compared to sub-
jects with the genotypes T/C and T/T, and achieved better
early response (12 weeks), at the end of treatment (48 weeks)
and SVR. Alanine aminotransferase activity was similar
among the groups. Tolerance of therapy was similar and inde-
pendent of the genotypes.
Conclusions: The study confirmed the dependence of
response to standard treatment of CH-C caused by the geno-
Streszczenie
Wstęp: Leczenie przewlekłego zapalenia wątroby typu C
(PZW-C) pegylowanym interferonem α (Peg-IFN) z ryba wiryną
powoduje tzw. trwałą odpowiedź wirusologiczną (sustained
virological response – SVR) u blisko 50% chorych. Odpowiedź
ta ściśle zależy od HCV i czynników genetycznych chorego.
Wykazano, że polimorfizm genu IL28B wiąże się z eradykacją
wirusa i SVR. 
Cel: Zbadanie, czy wyniki leczenia PZW-C u chorych z regionu
Polski Południowej zależą od wariantów genetycznych IL28B,
a polimorfizm może być czynnikiem predykcyjnym SVR.
Materiał i metody: Sto czterdzieści dwie osoby z PZW-C spo-
wodowanym genotypem 1b HCV leczono standardowo Peg-
IFN z rybawiryną przez 48 tygodni. Polimorfizmy rs12979860
IL28B (C/T) badano metodą PCR-RFLP. HCV-RNA i aktywność
aminotransferazy alaninowej (ALT) w surowicy mierzono
przed leczeniem i po 12, 48 i 72 tygodniach terapii.
Wyniki: Wiremia HCV-RNA przed terapią i po 12-tygodniowym
leczeniu była wyższa u chorych z genotypem T/C i T/T. Trwałą
odpowiedź wirusologiczną osiągnęło istotnie więcej chorych
z genotypem C/C (71,1%) w porównaniu z 41,4% z genotypem
T/C i 23,5% T/T. Chorzy z genotypem C/C lepiej reagowali na
leczenie w porównaniu z osobami z genotypami T/C i T/T,
osiągali wyższe wskaźniki odpowiedzi wczesnej (12 tygodni),
na koniec leczenia (48 tygodni) i SVR. Aktywność ALT nie 
różniła się istotnie podczas terapii pomiędzy grupami. Tole-
rancja leczenia była podobna i nie zależała od genotypów C/C,
T/C i T/T.
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type 1b HCV on the patient's genetic predisposition. In con-
trast to some other reports, poor prognosis was observed in
T/T homozygotes of IL28B.
Wnioski: Wyniki badania potwierdziły zależność odpowiedzi
na standardowe leczenie PZW-C spowodowanego genoty-
pem 1b HCV od predyspozycji genetycznej chorego, jednak
w przeciwieństwie do niektórych doniesień złe rokowanie
obserwowano u homozygot T/T IL28B. 
Introduction
Hepatitis C virus (HCV) infection is a serious global
problem, with the number of affected individuals world-
wide approximating 170 million people and about 0.7 mil-
lion individuals in Poland. The virus causes chronic hepa-
titis, liver cirrhosis and hepatocellular carcinoma. The
standard antiviral therapy is pegylated interferon α (Peg-
IFN) and ribavirin, but treatment response is not satisfac-
tory. Sustained virological response (SVR), defined as
undetectable HCV-RNA in blood 6 months after 48 weeks
of treatment, is seen in 80% of subjects and is lower
(about 50%) in the HCV genotype 1 infection [1]. The effec-
tiveness of treatment depends on the HCV (genotype,
viral load) and the genetic host factors [2-4]. In recent
years, it has been shown that a single nucleotide poly-
morphism (SNP) in the region of the interleukin-28B 
(IL-28B) gene significantly correlates with spontaneous
elimination of HCV and SVR [5]. The SNP rs12979860 was
described in the IL28B region and the investigators
demonstrated that the genetic profile is associated with
favourable alleles C/C IL28B [2-7]. However, variants of the
T/C or T/T IL28B gene are characterized by a lower per-
centage of SVR. The pharmacogenetics of chronic hepati-
tis is associated with a dependence of IL28B genotyping
with the elimination of HCV and is important in the indi-
vidualization of therapy, predicting the effectiveness and
costs [3, 8].
The HCV genotype 1b occurs in more than 80% of
patients in Poland [9], and the association of the response
to treatment with the IL28B genetic determinant in this
population has not been previously evaluated. 
Aim
The aim of this study was to investigate whether in
patients with chronic hepatitis caused by the HCV
genotype 1b from the region of southern Poland, the
HCV treatment outcomes depend on the rs12979860
variant in IL28B, and also whether this polymorphism
can be considered a predictor of response to therapy.
Material and methods
The study included 142 consecutive adult patients of
a Slavic ethnic origin, with chronic hepatitis induced by
the HCV genotype 1b, who reported for treatment at
University Hospital in Krakow and met the following cri-
teria. Inclusion criteria: anti-HCV and HCV-RNA present
in the serum and elevated alanine aminotransferase
(ALT), evaluated at least 6 months before inclusion, his-
tological examination confirming chronic hepatitis, body
mass index (BMI) below 30 kg/m2. Exclusion criteria:
decompensated cirrhosis, liver cancer, HBV or HIV infec-
tion, autoimmune liver disease, alcohol abuse, diabetes,
dyslipidaemia, severe chronic diseases, immunosuppres-
sive therapy.
The patients were treated for 48 weeks: Peg-IFN 
α-2a (Roche), 180 μg/kg subcutaneously once per week
with ribavirin (Roche) orally, 1-1.2 g daily or Peg-IFN α-2b
(Schering-Plough, MSD) 1.5 μg/kg of body weight once
a week with ribavirin (Schering-Plough, MSD), 1-1.2 g
daily. After treatment, the patients were followed for 24
weeks. 
The study was conducted in accordance with the
Helsinki Declaration of 1975, and the patients were
informed about the study and provided written consent
to participate in the study.
Serum anti-HCV, HCV-RNA and ALT were determined.
HCV-RNA was measured by reverse transcriptase – poly-
merase chain reaction (RT-PCR) (Cobas TaqMan HCV
Test v. 2.0, Roche Molecular Systems, Inc., USA). HCV-
RNA and ALT were determined before treatment and
after 12, 48 and 72 weeks. Early virological response
(EVR) was defined as undetectable HCV-RNA or at least
a 2-log drop in HCV RNA from the baseline at week 12 of
treatment; end treatment response (ETR) was defined
as undetectable HCV-RNA at the end of the 48-week
treatment.
Liver biopsies were performed within the 12 months
prior to enrolment. Biopsies containing at least 6 portal
spaces were stained with haematoxylin and eosin, the
Gomori-Masson method and trichrome for the presence
of connective tissue. In staging the fibrotic liver
changes, the Batts and Ludwig scale was applied. The
characteristics of patients are shown in Table I.
Genomic DNA was isolated from peripheral blood
samples using proteinase K – a set of ion-exchange
extraction column (A&A Biotechnology, Gdynia, Poland).
An amplification product 190 bp in length was obtained
using a standard PCR with primers 5'-GCC TCT TCC TCC
TGC GGG ACA AG and 5'-GCG CGG GCA AGT ATT CAA
CCC T Bsh1236I. After digestion with endonuclease, 
the resulting products were distributed in the agarose
gel electrophoresis. Option C was digested with the
enzyme. All the laboratory procedures were carried out
on blinded samples.
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Statistical analysis
Statistical analysis was performed using the chi-
square test and Fisher's exact probability test to com-
pare categorical variables. After analysis of results with
the Shapiro-Wilk test, the results were compared by the
Wilcoxon-Mann-Whitney U-test, Kruskal-Wallis test or
Student’s t-test. The analyses were performed using
Statistica v. 9.0 (StatSoft, Inc., USA). The results are pre-
sented as mean values and standard deviations (SD),
and p < 0.05 in the two-sided test was taken as statis-
tically significant.
Results
The genotyping of IL28B showed the presence of the
genotype C/C in 38 patients (26.8%), genotype T/C in 70
patients (49.2%) and genotype T/T in 34 patients (24%).
HCV-RNA viral load in serum of patients before treat-
ment and after 12 weeks, during the evaluation of early
response to therapy in the groups of genotypes C/C, T/C
and T/T, is shown in Table II. The baseline viral load was
not significantly lower in patients with the genotype
C/C (2.82 ±3.17 × 106 IU/ml) as compared to individuals
with T/C and T/T (respectively: 5.08 ±8.27 and 3.85
±6.36 × 106 IU/ml). HCV-RNA viral load after 12 weeks of
treatment in patients with the genotype C/C was sig-
nificantly (p < 0.01) lower (0.01 ±0.02 × 106 IU/ml) as
compared with T/C and much lower than in the geno-
type T/T (Table II). Additionally, the Spearman's rank cor-
relation performed between HCV-RNA viral load and ALT
activity in patients before treatment and after 12 weeks
of therapy did not confirm the presence of any signifi-
cant relationships.
Among all patients treated with Peg-IFN and rib-
avirin, 38% achieved EVR, 69.7% achieved ETR, and
44.4% achieved SVR. Response to treatment depending
on the genotypes C/C, T/C and T/T of IL28B is shown in
Table II. The EVR, ETR and SVR in patients with the geno-
type C/C as compared with the genotypes T/C and T/T
were significantly higher. The SVR, which is the criterion
of the effectiveness of HCV infection therapy, was
achieved in 71.1% of patients with the genotype C/C of
IL28B, compared with 41.4% in patients with the geno-
type T/C, and 23.5% in the genotype T/T (p = 0.006).
Tolerance of treatment was similar and independent of
the genotypes C/C, T/C and T/T of IL28B.
The ALT activity assessed at the baseline and after 12,
24, 48 and 72 weeks did not differ significantly between
the groups with the genotypes C/C, T/T and T/C.
Thus, the independent predictors of SVR in patients
with the genotype C/C of IL28B and infected with the
difficult to treat HCV genotype 1b were: viral load after
12 weeks of treatment, EVR, and ETR; and in patients
Parameter C/C T/C T/T Value of p
(n = 38) (n = 70) (n = 34)
Age [years] 42.2 ±11.6 45.2 ±10.5 44.2 ±13.6 0.698
Women, n (%) 14 (36.8) 32 (45.7) 14 (41.2) 0.544
Men, n (%) 24 (63.2) 38 (54.3) 20 (58.8)
Duration of 9.7 ±2.7 11.4 ±3.1 8.5 ±1.9 0.420
infection [years]
Body mass index 28.1 ±4.5 25.3 ±3.2 26.6 ±4.5 0.106
[kg/m2]
Viral load, 2.82 ±3.17 5.08 ±8.27 3.85 ±6.36 0.560
× 106 IU/ml 
Liver fibrosis, n (%)
F0-2 28 (73.7) 60 (85.7) 26 (76.5) 0.210
F3-4 10 (26.3) 10 (14.3) 8 (23.5) 0.125
ALT [U/l] 74.1 ±27.6 88.0 ±31.0 118.6 ±36.7 0.330
Peg-IFN α-2a, 20 (52.6) 34 (48.6) 14 (41.2) 0.954
n (%)
Peg-IFN α-2b, 18 (47.4) 36 (51.4) 20 (58.8)
n (%)
Table I. Characteristics of patients with chronic
hepatitis treated with Peg-IFN and ribavirin
depending on the genotypes of IL28B
Tabela I. Charakterystyka chorych na przewlekłe
zapalenie wątroby leczonych Peg-IFN i rybawiry-
ną w zależności od genotypu IL28B
Mean ± SD, n – number, p for Fisher's test, liver fibrosis according
to Batts-Ludwig (F0-2 less advanced, F3-4 more advanced)
C/C T/C T/T Value of p
(n = 38) (n = 70) (n = 34) CC vs. TC 
and TT
HCV-RNA viral load (value × 106 IU/ml)
Before treatment 2.82 ±3.17 5.08 ±8.27 3.85 ±6.36 NS
After 12 weeks 0.01 ±0.02 0.09 ±0.13 0.35 ±0.75 0.01
Response to therapy, n (%)
Early – EVR 24 (63.2) 24 (34.3) 6 (17.7) 0.025
End of therapy – 35 (92.1) 47 (67.1) 18 (52.9) 0.043
ETR
Sustained – SVR 27 (71.1) 29 (41.4) 8 (23.5) 0.006
Table II. HCV-RNA viraemia during treatment
and response of patients to therapy of chronic
hepatitis depending on the genotypes of IL28B
Tabela II. Wiremia HCV-RNA podczas leczenia 
i odpowiedź na terapię chorych na przewlekłe
zapalenie wątroby w zależności od genotypu
IL28B
Mean ± SD, n – number, p for Fisher’s test, NS – not significant 
(p > 0.05), vs. = one against another, virological response: EVR – 12
weeks, ETR – 48 weeks, SVR – 6 months after the 48-week treatment
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with elevated ALT at the baseline, they were enzyme
activity after 4 and 12 weeks of therapy.
Discussion
Genetic studies have shown that in patients with
chronic hepatitis caused by the HCV gene, polymor-
phism rs12979860 in IL28B is closely related to the
effectiveness of treatment with Peg-IFN and ribavirin 
[4-6, 10]. Moreover, it has been shown that genetic alter-
ations in IL28B may be predictors of response to this
treatment [3, 4, 10-13]. The association of host genetic
changes with the treatment outcome in patients with
chronic hepatitis have not yet been tested in a popula-
tion of Polish patients infected with the HCV genotype
1b. We have shown that HCV-RNA in serum of patients
at the baseline did not differ significantly among
patients with the genotypes C/C, T/C and T/T IL28B.
However, after 12 weeks of treatment, HCV-RNA viral
load was significantly lower in patients with the geno-
type C/C versus T/T and did not differ between the
genotypes C/C and T/C. These results differ from previ-
ous studies of other authors who showed a higher ini-
tial viral load of the HCV genotype C/C in an American
population [6, 11]. Early treatment response (EVR)
reached 63.2% in patients with the genotype C/C, was
significantly lower (34.3%) in individuals with the geno-
type T/C, and was only 17.7% in T/T. These results are
poorer than those obtained by other authors [2, 4].
Thompson et al. described EVR in 87% of patients with
the genotype C/C IL28B and in 38% and 28%, respec-
tively, of patients with the genotype T/C and T/T [4].
These differences may be due to a different patient pop-
ulation and an initial viral load, which are prognostic fac-
tors of response [2]. Several authors have also con-
firmed a significantly better response to treatment in
patients with the genotype C/C compared to the geno-
types T/C and T/T [2, 4, 7].
Virological response at the end of treatment (ETR)
reached 92.1% in patients with the genotype C/C, 67.1%
with T/C, and only 52.9% with the genotype T/T. These
results are similar to other studies [4-6]. The SVR is the
most important indicator of treatment efficacy of
patients with HCV. In this study, SVR was observed in
71.1% of patients with the genotype C/C and was signif-
icantly (p = 0.03) lower in subjects with the genotype
T/C (41.4%) and with the genotype T/T (23.5%). The mul-
tivariate analysis showed that the genotype C/C of
IL28B was associated with a significantly higher inci-
dence of ETR and SVR achieved by the patients. The
results of these studies are similar to those presented
by other authors [4-6].
The mean ALT level exceeded the upper normal lim-
it at the baseline in all the groups and during treatment
was similar regardless of the genotype IL28B. Contrary
results were obtained by other authors who observed
higher ALT in patients with the genotype C/C as com-
pared with T/C and T/T [11]. It should be noted that nor-
mal ALT activities are often recorded in patients with
chronic hepatitis caused by HCV. 
In conclusion, patients with chronic hepatitis caused
by the difficult-to-treat HCV genotype 1b treated with
Peg-IFN and ribavirin achieved a sustained virological
response, which in patients with the genotype C/C
IL28B was significantly better in comparison to the
genotype T/C (71.1% vs. 41.4%) and the genotype T/T
(71.1% vs. 23.5%). The study confirmed, in a patient pop-
ulation from the region of southern Poland, that the
response to standard treatment of HCV genotype 1b
chronic hepatitis depends on polymorphism of the IL28B
gene, which may be a predictor of virus elimination in
these patients.
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